Results 171 to 180 of about 33,915 (216)
The role of genetic polymorphisms on drug response in Alzheimer's disease: a systematic review. [PDF]
BMC Med GenomicsClimacosa FMM +12 more
europepmc +1 more source
Clinical effect of donepezil hydrochloride in the treatment of Parkinson's disease patients: a meta-analysis. [PDF]
Am J Transl ResZhu M, Liang C, Feng W, Qin J, Zhao W.
europepmc +1 more source
Neuroimaging and molecular mechanism of action of Cang-ai volatile oil in the treatment of vascular cognitive impairment. [PDF]
Front NeurosciChen B +6 more
europepmc +1 more source
Identification of stigmasterol derived AChE inhibitors for Alzheimer's disease using high throughput virtual screening and molecular dynamics simulations. [PDF]
Sci RepRahman MO +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs & Aging, 1997
Donepezil is a specific and potent acetylcholinesterase inhibitor according to in vitro data. It displays primarily noncompetitive inhibitory activity. In vivo, donepezil inhibited acetylcholinesterase activity in human erythrocytes and increased extracellular acetylcholine levels in the cerebral cortex and hippocampus of the rat.
H M, Bryson, P, Benfield
openaire +3 more sources
Donepezil is a specific and potent acetylcholinesterase inhibitor according to in vitro data. It displays primarily noncompetitive inhibitory activity. In vivo, donepezil inhibited acetylcholinesterase activity in human erythrocytes and increased extracellular acetylcholine levels in the cerebral cortex and hippocampus of the rat.
H M, Bryson, P, Benfield
openaire +3 more sources
Drugs of Today, 1998
Donepezil is a highly selective, long-acting acetylcholinesterase inhibitor which has been approved in numerous countries for the treatment of Alzheimer's disease. Donepezil increases the levels of acetylcholine in the brain of patients with Alzheimer's disease and presumably corrects some dysfunction associated with loss of cells in the basal ...
+5 more sources
Donepezil is a highly selective, long-acting acetylcholinesterase inhibitor which has been approved in numerous countries for the treatment of Alzheimer's disease. Donepezil increases the levels of acetylcholine in the brain of patients with Alzheimer's disease and presumably corrects some dysfunction associated with loss of cells in the basal ...
+5 more sources
Drugs & Aging, 2003
Vascular dementia (VaD), caused by stroke or small vessel disease, is the second most common form of dementia after Alzheimer's disease (AD). Donepezil, an acetylcholinesterase inhibitor currently indicated for use in patients with mild to moderate AD, has recently been evaluated in VaD.
David R, Goldsmith, Lesley J, Scott
openaire +2 more sources
Vascular dementia (VaD), caused by stroke or small vessel disease, is the second most common form of dementia after Alzheimer's disease (AD). Donepezil, an acetylcholinesterase inhibitor currently indicated for use in patients with mild to moderate AD, has recently been evaluated in VaD.
David R, Goldsmith, Lesley J, Scott
openaire +2 more sources